Abstract
The approval of sipuleucel-T for the treatment of patients with metastatic asymptomatic and minimally symptomatic castration-resistant prostate cancer (CRPC) has validated immunotherapy, in general, as a valid approach for this disease. Multiple novel immune based approaches including adenoviral-based vector delivering targeted antigen, DNAbased vaccination, listeria-based vaccination, pox-viral based approach, immune checkpoint blockade and radioimmunoconjugates appear promising. In concert with the development of new immunotherapeutics, the development of optimal intermediate endpoints for clinical efficacy, measures of an optimal immune response and biomarkers predictive for benefit are warranted. We briefly review emerging immunotherapeutic approaches to treat patients with CRPC.
Keywords: Immunotherapy, Castration resistant, Prostate cancer, Sipuleucel-T, Immunotherapy, Novel
Current Cancer Therapy Reviews
Title:Approaches Used in Immunotherapy for Prostate Cancer
Volume: 8 Issue: 4
Author(s): Guru Sonpavde
Affiliation:
Keywords: Immunotherapy, Castration resistant, Prostate cancer, Sipuleucel-T, Immunotherapy, Novel
Abstract: The approval of sipuleucel-T for the treatment of patients with metastatic asymptomatic and minimally symptomatic castration-resistant prostate cancer (CRPC) has validated immunotherapy, in general, as a valid approach for this disease. Multiple novel immune based approaches including adenoviral-based vector delivering targeted antigen, DNAbased vaccination, listeria-based vaccination, pox-viral based approach, immune checkpoint blockade and radioimmunoconjugates appear promising. In concert with the development of new immunotherapeutics, the development of optimal intermediate endpoints for clinical efficacy, measures of an optimal immune response and biomarkers predictive for benefit are warranted. We briefly review emerging immunotherapeutic approaches to treat patients with CRPC.
Export Options
About this article
Cite this article as:
Sonpavde Guru, Approaches Used in Immunotherapy for Prostate Cancer, Current Cancer Therapy Reviews 2012; 8 (4) . https://dx.doi.org/10.2174/1573394711208040238
DOI https://dx.doi.org/10.2174/1573394711208040238 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Hypoxia-Inducible Factor-1 (HIF-1) Signaling in Therapeutics: Implications for the Treatment of Inflammatory Bowel Disease
Recent Patents on Inflammation & Allergy Drug Discovery Cutting the Limits of Aminobisphosphonates: New Strategies for the Potentiation of their Anti-Tumour Effects
Current Cancer Drug Targets Therapeutic Drugs in Bone Loss-Associated Disorders: Clinical Outcomes and Challenges
Current Drug Targets Dietary Prevention of Cancer: Anticancer and Antiangiogenic Properties of Green Tea Polyphenols
Medicinal Chemistry Reviews - Online (Discontinued) The Role of CD40 Expression in Dendritic Cells in Cancer Biology; A Systematic Review
Current Cancer Drug Targets A hypothesis for the role of RECK in angiogenesis
Current Vascular Pharmacology Persistent GP130/STAT3 Signaling Contributes to the Resistance of Doxorubicin, Cisplatin, and MEK Inhibitor in Human Rhabdomyosarcoma Cells
Current Cancer Drug Targets Microdialysis in Drug Discovery
Current Drug Discovery Technologies The Critical Role of Insulin-Like Growth Factor-1 Isoforms in the Physiopathology of Skeletal Muscle
Current Genomics Multi-Nuclear Platinum Drugs: A New Paradigm in Chemotherapy
Current Medicinal Chemistry - Anti-Cancer Agents Emergence of Ad-Mediated Combination Therapy Against Cancer: What to Expect?
Current Cancer Drug Targets The Current Role of PET/CT in Radiotherapy Planning
Current Radiopharmaceuticals Melanin-Concentrating Hormone as a Metabolic and Cognitive Regulatory Factor
Current Medicinal Chemistry - Central Nervous System Agents The Application of Fungal Beta-glucans for the Treatment of Colon Cancer
Anti-Cancer Agents in Medicinal Chemistry Insulin Resistance, Glycemic Control and Adiposity: Key Determinants of Healthy Lifespan
Current Alzheimer Research Meet the Editorial Board:
Anti-Cancer Agents in Medicinal Chemistry The Neurotrophic and Antiangiogenic Functions of PEDF: A Reflection of its Variable Phosphorylation States
Current Genomics Silence of the Genes: A Targeted Approach to the Suppression of Specific Genes in Human Disease Using Small Interfering RNA (siRNA)
Current Genomics UCLA’s Molecular Screening Shared Resource: Enhancing Small Molecule Discovery with Functional Genomics and New Technology
Combinatorial Chemistry & High Throughput Screening Hydroxytyrosol Promotes Superoxide Production and Defects in Autophagy Leading to Anti-proliferation and Apoptosis on Human Prostate Cancer Cells
Current Cancer Drug Targets